NCT05389462TERMINATEDanonymous

A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Mipasetamab Uzoptirine (ADCT-601) Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With Selected Advanced Solid Tumors

Sponsor

Source record

ADC Therapeutics S.A.

Phase

Source record

Phase 1b

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Mipasetamab Uzoptirine (ADCT-601)

Indication / condition

AI-normalized

Advanced Solid Tumors

Intervention

Source record

ADCT-601, Gemcitabine

Related intelligence directories

Indication directory: Advanced Solid Tumors Modality directory: monoclonal antibody Target directory: Mipasetamab Uzoptirine (ADCT-601)

Source & freshness

Source record

NCT ID

NCT05389462

Original source

ClinicalTrials.gov

Source last updated

May 22, 2025

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT05389462

Title

A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Mipasetamab Uzoptirine (ADCT-601) Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With Selected Advanced Solid Tumors

Sponsor

ADC Therapeutics S.A.

Status

TERMINATED

Phase

Phase 1b

Condition raw

Advanced Solid Tumors

Condition normalized

Advanced Solid Tumors

Modality raw

Advanced Solid Tumors

Modality normalized

monoclonal antibody

Target raw

Mipasetamab Uzoptirine (ADCT-601)

Target normalized

Mipasetamab Uzoptirine (ADCT-601)

Interventions

ADCT-601, Gemcitabine

Public preview

Source record

ADC Therapeutics S.A. initiated a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ADCT-601 in patients with advanced solid tumors, particularly focusing on sarcomas and pancreatic cancer. The study aimed to establish the recommended phase 2 dose and assess the drug's efficacy in combination with gemcitabine.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

Investment-Ready Snapshot

A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Mipasetamab Uzoptirine (ADCT-601) Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With Selected Advanced Solid Tumors

Source & freshness

Public preview

Create an account to unlock this report

A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Mipasetamab Uzoptirine (ADCT-601) Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With Selected Advanced Solid Tumors

Investment-Ready Snapshot

Provenance

Protocol Description

Outcome Measures

Eligibility

Known Results And Readout Context

Patent And IP Landscape

Contacts